Dr. ir. M.M. Verbeek
Radboud University Medical Center
CAVIA: Cerebral Amyloid Angiopathy: Vascular Imaging and fluid markers of Amyloid deposition.
Alzheimer's disease & other dementias
Recent work by members of our project team strongly suggests that more specific diagnostic tests are within reach: (a) in cerebrospinal fluid (CSF) of CAA patients, an abnormal AbP40/AbP42 ratio is observed, distinguishing pure CAA from AD and supporting the concept of defining a potential CAA-specific AbP profile; (b) several AbP peptides and non-AbP proteins have been demonstrated (by in vitro/ex vivo studies) to be associated with CAA formation, but not with senile plaques, and may serve as candidate biomarkers for CAA; (c) MRI measures of hemodynamic response to neuronal activation are delayed and suppressed in CAA, supporting the concept that CAA can be diagnosed via MRI sequences detecting functional consequences of CAA. Both these CSF and MRI techniques have the intrinsic power to detect early changes in CAA development. In summary, the aim of this project is to develop and validate body fluid and neuroimaging methodologies to provide diagnostic tools to clinicians that will allow to detect CAA during life, to establish the contribution of CAA to cognitive decline and dementia, and to facilitate potential future personalized therapy.